Brief: Argenx: UplighTED Studies Of Efgartigimod SC In Thyroid Eye Disease To Be Discontinued
15/12/2025 06:04
Dec 15 (Reuters) - argenx SE ARGX.BR: PROVIDES UPDATE ON UPLIGHTED STUDIES OF EFGARTIGIMOD SC IN THYROID EYE DISEASE DISCONTINUES PHASE 3 UPLIGHTED STUDIES FOR TED DECISION BASED ON RECOMMENDATION FROM AN INDEPENDENT DATA MONITORING COMMITTEE TO STOP TRIALS FOR FUTILITY FOLLOWING ITS REVIEW OF DATA FROM A PRE-SPECIFIED INTERIM ANALYSIS Source text: ID:nGNE4VkYyk Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles